Yaron Werber
Stock Analyst at TD Cowen
(0.95)
# 3,667
Out of 4,847 analysts
41
Total ratings
32.14%
Success rate
-17.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yaron Werber
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWTX SpringWorks Therapeutics | Downgrades: Hold | $66 → $47 | $46.75 | +0.53% | 1 | Apr 29, 2025 | |
| ONC BeOne Medicines | Reiterates: Buy | $334 | $251.72 | +32.69% | 1 | Apr 24, 2025 | |
| FBRX Forte Biosciences | Initiates: Buy | n/a | $9.68 | - | 1 | Jan 21, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | n/a | $17.65 | - | 1 | Dec 20, 2024 | |
| SEPN Septerna | Initiates: Buy | n/a | $9.93 | - | 1 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $160 → $153 | $174.40 | -12.27% | 5 | Nov 15, 2024 | |
| BNTX BioNTech SE | Maintains: Hold | $132 → $122 | $115.64 | +5.50% | 5 | Nov 6, 2024 | |
| UPB Upstream Bio | Initiates: Buy | n/a | $10.85 | - | 1 | Nov 5, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $61 → $73 | $36.40 | +100.55% | 2 | Oct 21, 2024 | |
| EXEL Exelixis | Maintains: Buy | $27 → $34 | $42.67 | -20.32% | 2 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $59 | $34.76 | +69.74% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $67 | $28.43 | +135.67% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $10.90 | - | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.90 | - | 1 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.96 | - | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $19.87 | - | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $612 → $641 | $580.10 | +10.50% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.40 | - | 1 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $25 | $0.30 | +8,197.38% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.90 | - | 2 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $38 | $21.36 | +77.94% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.97 | - | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.51 | - | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.25 | - | 1 | Oct 26, 2021 |
SpringWorks Therapeutics
Apr 29, 2025
Downgrades: Hold
Price Target: $66 → $47
Current: $46.75
Upside: +0.53%
BeOne Medicines
Apr 24, 2025
Reiterates: Buy
Price Target: $334
Current: $251.72
Upside: +32.69%
Forte Biosciences
Jan 21, 2025
Initiates: Buy
Price Target: n/a
Current: $9.68
Upside: -
Dianthus Therapeutics
Dec 20, 2024
Initiates: Buy
Price Target: n/a
Current: $17.65
Upside: -
Septerna
Nov 19, 2024
Initiates: Buy
Price Target: n/a
Current: $9.93
Upside: -
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $160 → $153
Current: $174.40
Upside: -12.27%
BioNTech SE
Nov 6, 2024
Maintains: Hold
Price Target: $132 → $122
Current: $115.64
Upside: +5.50%
Upstream Bio
Nov 5, 2024
Initiates: Buy
Price Target: n/a
Current: $10.85
Upside: -
Ultragenyx Pharmaceutical
Oct 21, 2024
Maintains: Buy
Price Target: $61 → $73
Current: $36.40
Upside: +100.55%
Exelixis
Oct 21, 2024
Maintains: Buy
Price Target: $27 → $34
Current: $42.67
Upside: -20.32%
Jul 23, 2024
Maintains: Buy
Price Target: $54 → $59
Current: $34.76
Upside: +69.74%
Jul 15, 2024
Maintains: Buy
Price Target: $71 → $67
Current: $28.43
Upside: +135.67%
Mar 26, 2024
Upgrades: Buy
Price Target: n/a
Current: $10.90
Upside: -
Mar 18, 2024
Initiates: Outperform
Price Target: n/a
Current: $5.90
Upside: -
Mar 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.96
Upside: -
Dec 20, 2023
Initiates: Outperform
Price Target: n/a
Current: $19.87
Upside: -
Dec 12, 2023
Maintains: Outperform
Price Target: $612 → $641
Current: $580.10
Upside: +10.50%
Oct 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.40
Upside: -
Feb 28, 2023
Maintains: Market Perform
Price Target: $15 → $25
Current: $0.30
Upside: +8,197.38%
Nov 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $29.90
Upside: -
May 2, 2022
Initiates: Market Perform
Price Target: $38
Current: $21.36
Upside: +77.94%
Apr 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.97
Upside: -
Nov 30, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.51
Upside: -
Oct 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.25
Upside: -